In contrast, multiple myeloma showed a more complex mutational landscape with mutations in KRAS (33.3%), NRAS (33.3%), BRAF (18.5%), TP53 (26.9%), CCND1 (12.7%), FAM46C (1.9%), IRF4 (3.6%) and LTB (1.8%) genes, in line with previous studies (Table 3). The gene discussed is IRF4; the disease is plasma cell myeloma.